Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary

Pacira BioSciences’ third-quarter revenue declined 2% year over year, while net income increased. EXPAREL and ZILRETTA sales rose, but lower iovera° sales and the absence of prior-year royalty revenue weighed on revenue; earnings benefited from a $14.4 million contingent consideration gain and a $6…